文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

De Ritis 比值(天冬氨酸氨基转移酶/丙氨酸氨基转移酶)作为接受根治性膀胱切除术的膀胱癌患者的重要预后因素:一项倾向评分匹配研究。

De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.

机构信息

Department of Urology, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.

Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.

出版信息

Dis Markers. 2019 Aug 27;2019:6702964. doi: 10.1155/2019/6702964. eCollection 2019.


DOI:10.1155/2019/6702964
PMID:31534562
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6732616/
Abstract

INTRODUCTION: To investigate the correlation between preoperative De Ritis ratio (aspartate transaminase (AST)/alanine transaminase (ALT)) and postoperative outcome in patients with urothelial cell carcinoma (UC) treated with radical cystectomy. MATERIALS AND METHODS: We analyzed the clinical and pathological data of 771 patients who underwent radical cystectomy for bladder UC. Patients were divided into two groups according to the optimal value of AST/ALT ratio. The effect of the AST/ALT ratio was analyzed using the Kaplan-Meier method and Cox regression hazard models for patients' cancer-specific survival (CSS), overall survival (OS), and recurrence-free survival (RFS). In addition, propensity score matching of 1 : 1 was performed between the two groups. RESULTS: Median follow-up was 84.0 (36-275) months. Mean age was 64.8 ± 10.0 years. According to the receiver operating characteristic (ROC) analysis, the optimal threshold of the AST/ALT ratio was 1.1. In Kaplan-Meier analyses, the high AST/ALT group showed worse outcomes in CSS and OS (all < 0.001). Also, RFS ( = 0.001) in the Cox regression models of clinical and pathological parameters was used to predict CSS, OS, and AST/ALT ratio (HR 2.15, 95% CI 1.23-3.73, = 0.007) and pathological T stage (HR 4.80, 95% CI 1.19-19.28, = 0.003). To predict OS and AST/ALT ratio (HR 2.05, 95% CI 1.65-2.56, < 0.001), pathological T stage (HR 2.96, 95% CI 0.57-17.09, = 0.037) and positive lymph node (HR 1.71, 95% CI 1.50-1.91, = 0.021) were determined as independent prognostic factors. CONCLUSION: Preoperative AST/ALT ratio could be an independent prognostic factor in patients with UC treated with radical cystectomy.

摘要

简介:本研究旨在探讨根治性膀胱切除术治疗尿路上皮癌(UC)患者的术前 De Ritis 比值(天冬氨酸转氨酶(AST)/丙氨酸转氨酶(ALT))与术后结局之间的相关性。

材料与方法:我们分析了 771 例行根治性膀胱切除术的 UC 患者的临床和病理资料。根据 AST/ALT 比值的最佳值,将患者分为两组。采用 Kaplan-Meier 法和 Cox 回归风险模型分析 AST/ALT 比值对患者癌症特异性生存(CSS)、总生存(OS)和无复发生存(RFS)的影响。此外,对两组进行了 1∶1 的倾向评分匹配。

结果:中位随访时间为 84.0(36-275)个月。平均年龄为 64.8±10.0 岁。根据受试者工作特征(ROC)分析,AST/ALT 比值的最佳阈值为 1.1。Kaplan-Meier 分析显示,高 AST/ALT 组 CSS 和 OS 结局较差(均 <0.001)。此外,在临床病理参数的 Cox 回归模型中,RFS(=0.001)也可预测 CSS、OS 和 AST/ALT 比值(HR 2.15,95%CI 1.23-3.73,=0.007)和病理 T 分期(HR 4.80,95%CI 1.19-19.28,=0.003)。预测 OS 和 AST/ALT 比值(HR 2.05,95%CI 1.65-2.56,<0.001)、病理 T 分期(HR 2.96,95%CI 0.57-17.09,=0.037)和阳性淋巴结(HR 1.71,95%CI 1.50-1.91,=0.021)是独立的预后因素。

结论:术前 AST/ALT 比值可能是接受根治性膀胱切除术治疗的 UC 患者的独立预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/132b/6732616/3c46cb98e610/DM2019-6702964.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/132b/6732616/3c46cb98e610/DM2019-6702964.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/132b/6732616/3c46cb98e610/DM2019-6702964.001.jpg

相似文献

[1]
De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.

Dis Markers. 2019-8-27

[2]
Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study.

BMC Urol. 2021-9-27

[3]
The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.

Int Urol Nephrol. 2017-9

[4]
De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.

BJU Int. 2017-2

[5]
Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.

BMC Urol. 2019-1-24

[6]
Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.

Clin Genitourin Cancer. 2017-4-20

[7]
The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.

Int Urol Nephrol. 2017-8

[8]
The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma.

Int Urol Nephrol. 2017-8

[9]
The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma.

Clin Genitourin Cancer. 2020-6

[10]
De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery.

Clin Genitourin Cancer. 2017-6

引用本文的文献

[1]
Prognostic Value of the De Ritis Ratio in Predicting Survival After Bladder Recurrence Following Nephroureterectomy for Upper Urinary Tract Tumors.

Diagnostics (Basel). 2025-7-22

[2]
Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

Cancers (Basel). 2023-12-6

[3]
Association between De Ritis ratio and intraoperative blood transfusion in patients undergoing surgical clipping of unruptured intracranial aneurysms: a single center, retrospective, propensity score-matched study.

Korean J Anesthesiol. 2024-4

[4]
A narrative review of peripheral blood parameters for urothelial carcinoma treated with systemic antitumor drugs.

Transl Androl Urol. 2023-5-31

[5]
Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis.

Int J Mol Sci. 2023-3-19

[6]
A Retrospective Analysis of the De Ritis Ratio in Muscle Invasive Bladder Cancer, with Focus on Tumor Response and Long-Term Survival in Patients Receiving Neoadjuvant Chemotherapy and in Chemo Naïve Cystectomy Patients-A Study of a Clinical Multicentre Database.

J Pers Med. 2022-10-27

[7]
Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy.

Front Oncol. 2022-5-18

[8]
Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study.

BMC Urol. 2021-9-27

[9]
Elevated De Ritis Ratio as a Predictor for Acute Kidney Injury after Radical Retropubic Prostatectomy.

J Pers Med. 2021-8-25

[10]
A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer.

Oncotarget. 2021-4-27

本文引用的文献

[1]
Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform.

Investig Clin Urol. 2019-5-20

[2]
Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.

BMC Urol. 2019-1-24

[3]
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

World J Urol. 2018-6-21

[4]
Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy.

Urol Oncol. 2017-12

[5]
The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.

Int Urol Nephrol. 2017-9

[6]
De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery.

Clin Genitourin Cancer. 2017-6

[7]
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.

Eur Urol. 2016-6-17

[8]
De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.

BJU Int. 2017-2

[9]
FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.

Eur J Radiol. 2016-3

[10]
Metabolic alterations in bladder cancer: applications for cancer imaging.

Exp Cell Res. 2016-2-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索